Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Mutation Status in Myelodysplastic Neoplasm and Acute Myeloid Leukemia: Impact of Reclassification Based on the 5th WHO and International Consensus Classification Criteria: A Korean Multicenter Study.
Ann Lab Med
November 2024
Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Background: mutations are associated with poor prognosis in myelodysplastic neoplasm (MDS) and AML. The updated 5th WHO classification and International Consensus Classification (ICC) categorize -mutated MDS and AML as unique entities. We conducted a multicenter study in Korea to investigate the characteristics of -mutated MDS and AML, focusing on diagnostic aspects based on updated classifications.
View Article and Find Full Text PDFHow long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.
Int J Gynecol Cancer
December 2024
Medical Oncology, Prince of Wales Hospital Nelune Comprehensive Cancer Centre, Sydney, New South Wales, Australia
Objective: There are no data, and thus no consensus, on the optimal duration of poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy for exceptional responders (here defined as progression-free for 5 years or longer) with platinum sensitive recurrent ovarian cancer. The current licence is to continue PARP inhibitors until progression or toxicity; however, international practice varies considerably. The risks of late progression and late-onset myeloid malignancies, defined as occurring beyond 5 years of PARP inhibition, are unknown.
View Article and Find Full Text PDFIncidence of hematologic cancer types in Japan by ICD-O-3 code: analysis of National Cancer Registry.
Future Sci OA
December 2024
Synix Inc., Tokyo, Japan.
We classified subtypes of hematologic cancer in Japan's National Cancer Registry (NCR) in 2016 by ICD-O-3 code and compared numbers with the Japanese Society of Hematology's Blood Diseases Registry (BDR). We reviewed data for individual cases, and calculated incidence per 100,000. NCR reported 67,919 cases of hematological cancer, including diffuse large B-cell lymphoma, Not Otherwise Specified (NOS) (11.
View Article and Find Full Text PDFSplicing the Difference: Harnessing the Complexity of the Transcriptome in Hematopoiesis.
Exp Hematol
December 2024
Section of Hematology, Department of Internal Medicine, Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut. Electronic address:
Article Synopsis
- Alternative splicing enhances the variety of RNA and proteins, playing a crucial role in hematopoiesis—the process of blood cell formation from stem cells.
- Aberrant splicing from mutations, particularly in the β-globin gene, is linked to diseases like thalassemia, while mutations in splicing factors are associated with myeloid malignancies and myelodysplastic syndromes.
- Recent advancements in flow cytometry and sequencing technologies allow for deeper insights into the regulation of blood cell development and the role of splicing in hematologic disorders.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!